Sulfalene
| Clinical data | |
|---|---|
| Trade names | Eadazine, Kelfizina, Kelfizine W, Longum |
| Other names | Sulfametopyrazine |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 60 to 80% |
| Elimination half-life | 60 to 65 hours |
| Excretion | Urinary |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.278 |
| Chemical and physical data | |
| Formula | C11H12N4O3S |
| Molar mass | 280.30 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Sulfalene (INN, USAN) or sulfametopyrazine (BAN) is a long-acting sulfonamide antibacterial used for the treatment of chronic bronchitis, urinary tract infections and malaria. As of 2014 there were only two countries in which it is currently still marketed: Thailand and Ireland.
It was discovered by researchers at Farmitalia and first published in 1960 and was marketed as Kelfizina.